Gastroenterology
Volume 133, Issue 5 , Pages 1414-1422, November 2007

A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis

  • Scott Plevy

      Affiliations

    • Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina
    • Corresponding Author InformationAddress requests for reprints to: Scott Plevy, MD, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill School of Medicine, 103 Mason Farm Road, Campus Box 7032, 7341C MBRB, Chapel Hill, North Carolina 27599-7032. fax: (919) 843-6899.
    • ,
  • Bruce Salzberg

      Affiliations

    • Atlanta Gastroenterology Associates, Atlanta, Georgia
    • ,
  • Gert Van Assche

      Affiliations

    • Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Miguel Regueiro

      Affiliations

    • Division of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    • ,
  • Daniel Hommes

      Affiliations

    • Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • William Sandborn

      Affiliations

    • Mayo Clinic, Rochester, Minnesota
    • ,
  • Stephen Hanauer

      Affiliations

    • Gastroenterology Clinic, University of Chicago Medical Center, Chicago, Illinois
    • ,
  • Stephan Targan

      Affiliations

    • Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California
    • ,
  • Lloyd Mayer

      Affiliations

    • Mount Sinai School of Medicine, New York, New York
    • ,
  • Uma Mahadevan

      Affiliations

    • Mt Zion Hospital, University of California, San Francisco, San Francisco, California
    • ,
  • Matthew Frankel

      Affiliations

    • PDL BioPharma, Inc, Fremont, California
    • ,
  • James Lowder

      Affiliations

    • PDL BioPharma, Inc, Fremont, California

Received 17 October 2006; accepted 2 August 2007. published online 23 August 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by the sponsor, PDL BioPharma, Fremont, CA.

 The authors declare the following conflicts of interest: consultant, PDL BioPharma (S.P., G.V., M.R., D.H., W.S., S.H., S.T., L.M., U.M.); research support for clinical trial, PDL BioPharma (S.P., B.S., G.V., M.R., D.H., W.S., S.H., S.T., L.M., U.M.); speaker at continuing medical education symposia sponsored by PDL BioPharma (S.P., W.S., S.H., D.H.).

 ClinicalTrials.gov identifier: NCT00032305.

PII: S0016-5085(07)01491-6

doi:10.1053/j.gastro.2007.08.035

Refers to article:

  • Continuing Medical Education Exam 1: November 2007

    Michael B. Wallace
    Gastroenterology November 2007 (Vol. 133, Issue 5, Pages 1690-1691)

Gastroenterology
Volume 133, Issue 5 , Pages 1414-1422, November 2007

Article Tools

* Image Usage & Resolution